

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/085251 A1

(51) International Patent Classification⁷: C07D 487/04,
519/00, A61K 31/5517, A61P 35/00

(21) International Application Number:
PCT/GB2005/000768

(22) International Filing Date: 1 March 2005 (01.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0404575.3 1 March 2004 (01.03.2004) GB
0426392.7 1 December 2004 (01.12.2004) GB


(71) Applicant (for all designated States except US):
SPIROGEN LIMITED [GB/GB]; 79 George Street,
Ryde Isle of Wight PO33 2JF (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **HOWARD, Philip, Wilson** [GB/GB]; 3 Westbourne Mews, The Maltings, St Albans Hertfordshire AL1 1LS (GB). **GREGSON, Stephen, John** [GB/GB]; 6 Warepoint Drive, Thamesmead, London Greater London SE28 0HJ (GB).

(74) Agents: **WATSON, Robert** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(54) Title: 11-HYDROXY-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPIN-5-ONE DERIVATIVES AS KEY INTERMEDIATES FOR THE PREPARATION OF C2 SUBSTITUTED PYRROLOBENZODIAZEPINES



(I)



(III)

(57) Abstract: The present inventors have developed a key intermediate for the production of C2 substituted PBDs, which has a leaving group at the C2 position, a carbamate protecting group at the N10 position and a protected hydroxy group at the C11 position. In a first aspect, the present invention comprises a compound with the formula (I), wherein: R¹⁰ is a carbamate-based nitrogen protecting group; R¹¹ is an oxygen protecting group; and R² is a labile leaving group. In a further aspect, the present invention comprises a method of synthesising a compound of formula (III), or a solvate thereof, from a compound of formula (I) as defined in the first aspect, R¹⁶ is either O-R¹¹, wherein R¹¹ is as defined in the first aspect, or OH, or R¹⁰ and R¹⁶

together form a double bond between N10 and C11; and R¹⁵ is R. The other substituents are defined in the claims. Further aspects of the present invention relate to compounds of formula (III) (including solvates thereof when R¹⁰ and R¹⁶ form a double bond between N10 and C11, and pharmaceutical salts thereof), pharmaceutical compositions comprising these, and their use in the manufacture of a medicament for the treatment of a proliferative disease.

WO 2005/085251 A1